Inrebic

Fedratinib, the active ingredient in Inrebic, is a Janus kinase (JAK) inhibitor presented as a tablet for oral use. It is indicated for the treatment of primary or secondary myelofibrosis in adult patients, addressing disease‑related splenomegaly and symptom burden.

GNH USA supplies Inrebic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing consistent quality and regulatory compliance for global oncology programs, and supporting clinical research initiatives through reliable supply chain management.

Fedratinib is a Janus kinase (JAK) inhibitor used in the management of myelofibrosis. - Primary myelofibrosis: reduces spleen size and improves disease‑related symptoms. - Secondary myelofibrosis (post‑polycythemia vera or post‑essential thrombocythemia): provides disease control comparable to primary disease. - Myelofibrosis with splenomegaly: decreases spleen volume and alleviates associated discomfort.

Fedratinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools that may require hydration. - Fatigue: persistent tiredness affecting daily activities. - Anemia: reduced red blood cell count leading to weakness. - Thrombocytopenia: lowered platelet levels increasing bleeding tendency.

Serious or Rare Side Effects: - Wernicke encephalopathy: neurological disorder linked to thiamine deficiency. - Severe infections: opportunistic bacterial, fungal, or viral infections. - Hepatic toxicity: elevated liver enzymes or liver injury. - Cardiac events: arrhythmias or heart failure in susceptible patients.

When prescribing Fedratinib, clinicians should consider several safety measures. - Dose adjustment: required in hepatic impairment to avoid excess exposure. - Monitor blood counts: watch for anemia, thrombocytopenia, and neutropenia. - Infection risk: assess for active infections and treat promptly. - Avoid strong CYP3A4 inhibitors: concomitant use may increase fedratinib levels. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Fedratinib interacts with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase fedratinib exposure. - Concomitant use with other JAK inhibitors: risk of additive myelosuppression. - Potent CYP3A4 inducers (e.g., rifampin): may substantially reduce efficacy.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may modestly raise plasma levels. - Anticoagulants (e.g., warfarin): monitor INR and bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): observe for enhanced bleeding tendencies.